White House economists project that President Donald Trump’s agreements with pharmaceutical companies to reduce some U.S. prescription drug prices to levels charged in other countries could save $529 billion over the next decade, according to an analysis obtained by The Associated Press and reported by multiple outlets. The projection is presented as the first economy-wide estimate linked to the policy, which Trump has used as a central element of his election messaging ahead of the November midterms. Under the approach described, drug prices in the U.S. would be narrowed relative to prices in other affluent nations. Democratic lawmakers have questioned the accuracy and scope of the savings figures, and the newly released numbers are expected to prompt further scrutiny of the underlying methodology. The reporting also notes that cost-of-living concerns are a major focus for voters, with broader economic pressures shaping public attention around affordability.
White House projects $529 billion savings from Trump drug pricing deals
White House economists project that President Donald Trump’s agreements with pharmaceutical companies to reduce some U.S. prescription drug prices to levels charged in other countries could save $529...
- The White House economists estimate $529 billion in prescription drug savings over 10 years from Trump-linked drug pricing deals.
- The deals aim to lower some U.S. prescription drug prices to levels charged in other countries.
- The projection is described as the first economy-wide assessment of the policy.
- Democratic lawmakers raise doubts about the claimed savings and are expected to question the analysis.
- The initiative is tied to Trump’s broader political messaging ahead of the November midterms.
WASHINGTON (AP) — White House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their U.S. prescription drug prices to what they charge in other countries could save $529 billion over the next 10 years. The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump's pitch to voters going into November's midterm elections for control of the House and Senate....
3 months agoWhite House economists estimate that President Donald Trump's deals with pharmaceutical companies to drop some of their US prescription drug prices to what they charge in other countries could save USD 529 billion over the next 10 years. The analysis obtained by The Associated Press includes the first economy-wide projections behind a policy at the core of Trump's pitch to voters going into November's midterm elections for control of the House and Senate. Democratic lawmakers have been doubtful about the savings claimed by Trump and these new numbers are likely to trigger additional questions about the data. Cost-of-living issues are at the forefront of voters' concerns and higher energy prices tied to the Iran war have deepened the public's anxiety. Trump has tried in part to address affordability concerns by focusing on his efforts to cut deals with companies so that the cost of prescription drugs in the US would no longer be dramatically higher than in other affluent nations. "
3 months ago
US banks form BankChain Alliance to develop nationwide blockchain network by 2027
US banking groups plan to create a shared nationwide blockchain network known as the “BankChain Alliance,” with a target...
WHO and partners report rising Ebola cases and deaths in DR Congo, with Uganda confirmations
An Ebola outbreak continues to spread in the eastern Democratic Republic of the Congo (DRC), with international agencies...
US moves to target Palestine Action in counterterrorism effort focused on ‘far-left’ groups
The US is taking steps to target Palestine Action as part of a counterterrorism effort aimed at groups described as “far...